MEDICINOVA INC
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
MNOV$1.40-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues | $— | $1,000,000 |
| Operating expenses: | ||
| Research, development and patents | 7,194,731 | 5,657,895 |
| General and administrative | 5,480,600 | 5,242,370 |
| Total operating expenses | 12,675,331 | 10,900,265 |
| Operating loss | (12,675,331) | (9,900,265) |
| Interest income | 1,670,804 | 1,834,665 |
| Other expense, net | (39,485) | (502,869) |
| Loss before income taxes | (11,044,012) | (8,568,469) |
| Income tax expense | (5,537) | (3,047) |
| Net loss | $(11,049,549) | $(8,571,516) |
| Basic and diluted net loss per common share | $(0.23) | $(0.17) |
| Shares used to compute basic and diluted net loss per common share | 49,046,246 | 49,046,246 |
| Net loss | $(11,049,549) | $(8,571,516) |
| Other comprehensive loss, net of tax: | ||
| Foreign currency translation adjustments | (17,064) | (2,805) |
| Comprehensive loss | $(11,066,613) | $(8,574,321) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.